Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses

Inclusion Criteria: * Patients with Type 2 diabetes who were new users of Linagliptin or new users of Glimepiride and: \- Had no more than 3 anti-diabetic drugs including index drug * AND at elevated risk of cardiovascular (CV) events according to specific criteria: * Previous vascular disease * Evidence of vascular-related end-organ damage * Age ⩾ 70 years * ⩾ 2 CV risk factors: * Treated hypertension * Smoking * Using any lipid lowering treatment * Age ≥ 40 and ≤ 85 years at treatment initiation Exclusion Criteria: * Patients with Type 1 Diabetes Mellitus * Previous exposure to dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones (TZDs), insulin or sodium glucose co-transporter-2 (SGLT-2s). * Exclude anti-diabetic background therapy if initiated in 2 months prior * Morbid obesity or treatment with anti-obesity drugs 3 months prior to treatment initiation * Severe hyperglycemia * Active liver disease or impaired hepatic function * Any previous bariatric surgery * Coronary artery re-vascularisation ≤ 6 weeks prior to treatment initiation * Prior hospitalization for congestive heart failure * Acute or chronic metabolic acidosis * Hereditary galactose intolerance * Alcohol or drug abuse within the 3 months prior to treatment initiation * Use of oral corticosteroids * Pregnant women * Patients with cancer * Acute coronary syndrome ≤ 6 weeks prior to treatment initiation * Stroke or Transient …